(Date:12/11/2009)... Researchers have discovered a new explanation for differences in the ... of a certain gene, the more serious the handicap. The ... suspected that it is the amount of copies of the ... in the American Journal of Human Genetics , and ... Froyen connected to VIB, a life sciences research institute in ...
(Date:12/11/2009)... Corporation announced today the enrollment and dosing at the ... the first patient in the ACE ( AC ... 2 pivotal trial in patients with relapsed or refractory ... orally available, potent and highly selective small molecule that ... inhibitor. The ACE study is designed to be ...
(Date:12/11/2009)... Bio Innovations (MBI) today announces 2 new additions ... joined MBI as Senior Vice President of Commercial ... aspects of the company, including sales, marketing, and ... joined MBI as Vice President of Process Development, ... its broad pipeline of products to commercial manufacturing ...
(Date:12/11/2009)... CALGARY, Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... today announced the appointment of Dr. Alan Warrander ... Licensing and Business Development. ,, "Dr. Warrander will ... licensing strategy for REOLYSIN(R)," said Dr. Brad Thompson, ... agreement on the design of a Phase 3 ...
Breaking Biology Technology:Amount of gene surplus determines severity of mental retardation in males 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3